Details

Autor(en) / Beteiligte

• Sitbon, Olivier
• Channick, Richard
• Chin, Kelly M
• Frey, Aline
• Gaine, Sean
• Galiè, Nazzareno
• Ghofrani, Hossein-Ardeschir
• Hoeper, Marius M
• Lang, Irene M
• Preiss, Ralph
• Rubin, Lewis J
• Di Scala, Lilla
• Tapson, Victor
• Adzerikho, Igor
• Liu, Jinming
• Moiseeva, Olga
• Zeng, Xiaofeng
• Simonneau, Gérald
• McLaughlin, Vallerie V

Titel

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Ist Teil von

• The New England journal of medicine, 2015-12, Vol.373 (26), p.2522-2533

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Among over 1100 patients with pulmonary arterial hypertension who received selexipag, an oral selective IP prostacyclin-receptor agonist, or placebo, the risk of the composite end point of death or complication was lower with selexipag than with placebo at 1.3 years of follow-up. Pulmonary arterial hypertension is a severe disease with a poor prognosis despite available treatment options. 1 Current recommendations support the use of a combination of therapies that target the endothelin, nitric-oxide, and prostacyclin pathways. 2 , 3 Despite the benefits of intravenous prostacyclin therapy, 2 , 4 many patients with pulmonary arterial hypertension die without ever receiving this treatment. 5 , 6 The burden and risks related to the administration of prostacyclin therapy are probably contributing factors. 7 Selexipag is an oral selective IP prostacyclin-receptor agonist that is structurally distinct from prostacyclin. 8 – 11 In a placebo-controlled, phase 2 trial involving patients who were already receiving treatment for pulmonary . . .